Tempus AI (TEM) 10-Q 6 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2024	Aug. 06, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-42130
Entity Registrant Name	Tempus AI, Inc.
Entity Central Index Key	0001717115
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4903308
Entity Address, Address Line One	600 West Chicago Avenue
Entity Address, Address Line Two	Suite 510
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	800
Local Phone Number	976-5448
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Trading Symbol	TEM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		149,274,923
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		5,043,789

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 478,811	$ 165,767
Accounts receivable, net of allowances of $1,092 and $1,115 at June 30, 2024 and December 31, 2023, respectively	118,106	94,462
Inventory	32,690	28,845
Warrant asset	800	5,070
Prepaid expenses and other current assets	29,704	17,295
Marketable equity securities	11,255	31,807
Deferred offering costs	0	7,085
Total current assets	671,366	350,331
Property and equipment, net	60,539	61,681
Goodwill	73,345	73,354
Warrant asset, less current portion	1,500	4,930
Intangible assets, net	16,252	21,916
Investments and other assets	7,677	8,971
Warrant contract asset, less current portion	19,077	21,499
Operating lease right-of-use assets	13,994	20,530
Restricted cash	861	840
Total Assets	864,611	564,052
Current Liabilities
Accounts payable	28,646	54,421
Accrued expenses	85,185	82,517
Deferred revenue	50,905	64,860
Other current liabilities	7,273	8,213
Operating lease liabilities	5,828	6,437
Accrued data licensing fees	3,727	6,382
Accrued dividends	0	9,797
Total current liabilities	181,564	232,627
Operating lease liabilities, less current portion	27,238	32,040
Convertible promissory note	180,648	193,124
Warrant liability	33,600	34,500
Other long-term liabilities	16,790	19,751
Interest payable	62,608	55,321
Long-term debt, net	261,853	256,541
Deferred revenue, less current portion	2,059	16,768
Total Liabilities	766,360	840,672
Commitments and contingencies
Convertible redeemable preferred stock, $0.0001 par value, no and 69,803,765 shares authorized at June 30, 2024 and December 31, 2023, respectively; no and 63,525,953 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $0 and $1,130,429 at June 30, 2024 and December 31, 2023, respectively	0	1,105,543
Stockholders' equity (deficit)
Treasury Stock, 145,466 shares at June 30, 2024 and December 31, 2023, at cost	(3,602)	(3,602)
Additional Paid-In Capital	2,163,911	18,345
Accumulated Other Comprehensive (Loss) Income	(94)	5
Accumulated deficit	(2,061,980)	(1,396,917)
Total Stockholders' equity (deficit)	98,251	(1,382,163)
Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity (deficit)	864,611	564,052
Common Class A [Member]
Stockholders' equity (deficit)
Common stock value issued	15	6
Common Class B [Member]
Stockholders' equity (deficit)
Common stock value issued	1	0
Nonvoting Common Stock [Member]
Stockholders' equity (deficit)
Common stock value issued	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accounts receivable, net of allowances	$ 1,092	$ 1,115
Temporary equity shares authorized		69,803,765
Temporary equity shares outstanding		63,525,953
Temporary equity liquidation preference		$ 1,130,429
Treasury stock common shares	145,466	145,466
Redeemable Convertible Preferred Stock [Member]
Temporary equity par or stated value per share	$ 0.0001	$ 0.0001
Temporary equity shares authorized	0	69,803,765
Temporary equity shares issued	0	63,525,953
Temporary equity shares outstanding	0	63,525,953
Temporary equity liquidation preference	$ 0	$ 1,130,429
Common Class A [Member]
Common stock par or stated value per share	$ 0.0001	$ 0.0001
Common stock shares authorized	1,000,000,000	200,228,024
Common stock shares issued	149,274,923	58,367,961
Common stock shares outstanding	149,274,923	58,367,961
Common Class B [Member]
Common stock par or stated value per share	$ 0.0001	$ 0.0001
Common stock shares authorized	5,500,000	5,374,899
Common stock shares issued	5,043,789	0
Common stock shares outstanding	5,043,789	0
Nonvoting Common Stock [Member]
Common stock par or stated value per share	$ 0.0001	$ 0.0001
Common stock shares authorized	0	66,946,627
Common stock shares issued	0	5,205,802
Common stock shares outstanding	0	5,060,336

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net revenue
Total net revenue	$ 165,969	$ 132,417	$ 311,789	$ 248,041
Cost and operating expenses
Technology research and development	77,908	23,427	104,975	46,329
Research and development	68,025	22,171	92,365	43,034
Selling, general and administrative	463,072	71,189	542,636	140,236
Total cost and operating expenses	699,461	177,555	898,555	347,040
Loss from operations	(533,492)	(45,138)	(586,766)	(98,999)
Interest income	1,718	1,957	2,749	4,381
Interest expense	(13,295)	(11,712)	(26,533)	(20,903)
Other (expense) income, net	(7,048)	(766)	(6,299)	5,622
Loss before provision for income taxes	(552,117)	(55,659)	(616,849)	(109,899)
Provision for income taxes	(95)	(3)	(106)	(9)
Losses from equity method investments	0	(170)	0	(301)
Net Loss	(552,212)	(55,832)	(616,955)	(110,209)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares	(11,540)	(10,897)	(39,347)	(21,566)
Cumulative Undeclared Dividends on Series C preferred shares	(668)	(745)	(1,174)	(1,466)
Net loss attributable to common shareholders, basic	(564,420)	(67,474)	(657,476)	(133,241)
Net loss attributable to common shareholders, diluted	$ (564,420)	$ (67,474)	$ (657,476)	$ (133,241)
Net loss per share attributable to common shareholders, basic	$ (6.86)	$ (1.07)	$ (9.02)	$ (2.11)
Net loss per share attributable to common shareholders, diluted	$ (6.86)	$ (1.07)	$ (9.02)	$ (2.11)
Weighted-average shares outstanding used to compute net loss per share, basic	82,325	63,286	72,930	63,257
Weighted-average shares outstanding used to compute net loss per share, diluted	82,325	63,286	72,930	63,257
Comprehensive Loss, net of tax
Net loss	$ (552,212)	$ (55,832)	$ (616,955)	$ (110,209)
Foreign currency translation adjustment	(43)	53	(99)	25
Comprehensive loss	(552,255)	(55,779)	(617,054)	(110,184)
Genomics [Member]
Net revenue
Total net revenue	112,324	91,924	214,893	173,982
Cost and operating expenses
Cost of revenues	68,324	46,961	121,159	92,241
Data and services [Member]
Net revenue
Total net revenue	53,645	40,493	96,896	74,059
Cost and operating expenses
Cost of revenues	$ 22,132	$ 13,807	$ 37,420	$ 25,200

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities
Net loss	$ (616,955)	$ (110,209)
Adjustments to reconcile net loss to net cash used in operating activities
Change in fair value of warrant liability	(900)	(5,700)
Stock-based compensation	488,313	0
Gain on warrant exercise	(173)	0
Gain on marketable equity securities	(2,541)	0
Amortization of original issue discount	691	489
Amortization of deferred financing fees	255	255
Change in fair value of contingent consideration	165	0
Amortization of warrant contract asset	2,422	3,307
Depreciation and amortization	18,348	16,185
Provision for bad debt expense	327	1,376
Change in fair value of warrant asset	7,700	0
Loss from equity-method investments	0	301
Amortization of finance right-of-use lease assets	0	190
Non-cash operating lease costs	3,252	3,382
Minimum accretion expense	92	187
Impairment of intangible assets	0	7,359
PIK interest added to principal	4,366	297
Change in assets and liabilities
Accounts receivable	(23,971)	(6,850)
Inventory	(3,845)	(5,101)
Prepaid expenses and other current assets	(12,409)	(1,634)
Investments and other assets	1,294	(4,528)
Accounts payable	(33,371)	(4,195)
Deferred revenue	(28,669)	(19,974)
Accrued data licensing fees	(2,749)	(7,608)
Accrued expenses & other	(2,805)	8,125
Interest payable	7,287	7,611
Operating lease liabilities	(4,582)	(4,352)
Net cash used in operating activities	(198,458)	(121,087)
Investing activities
Purchases of property and equipment	(14,116)	(15,906)
Proceeds from sale of marketable equity securities	23,098	0
Business combinations, net of cash acquired	0	(2,869)
Net cash provided by (used in) investing activities	8,982	(18,775)
Financing activities
Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions	381,951	0
Tax withholding related to net share settlement of restricted stock units	(69,918)	0
Issuance of Series G-5 Preferred Stock	199,750	0
Principal payments on finance lease liabilities	0	(192)
Purchase of treasury stock	0	(3,602)
Payment of deferred offering costs	(2,714)	(151)
Dividends paid	(5,625)	(5,625)
Proceeds from long-term debt, net of original issue discount	0	48,750
Payment of indemnity holdback related to acquisition	(813)	0
Net cash provided by financing activities	502,631	39,180
Effect of foreign exchange rates on cash	(90)	28
Net increase (decrease) in Cash, Cash Equivalents and Restricted Cash	313,065	(100,654)
Cash, cash equivalents and restricted cash, beginning of period	166,607	303,731
Cash, cash equivalents and restricted cash, end of period	479,672	203,077
Cash, Cash Equivalents and Restricted Cash are Comprised of:
Cash and cash equivalents	478,811	202,266
Restricted cash and cash equivalents	861	811
Total cash, cash equivalents and restricted cash	479,672	203,077
Supplemental disclosure of cash flow information
Cash paid during the year for interest	13,921	5,691
Cash paid for income taxes	89	41
Supplemental disclosure of noncash investing and financing activities
Dividends Payable	5,487	4,545
Purchases of property and equipment, accrued but not paid	1,108	2,952
Deferred offering costs, accrued but not yet paid	6,051	2,917
Redemption of convertible promissory note	12,476	13,926
Non-voting common stock issued in connection with business combinations	344	4,305
Operating lease liabilities arising from obtaining right-of-use assets	0	892
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering	1,348,809	0
Reclassificiation of deferred offering costs to additional paid-in capital upon initial public offering	12,347	0
Taxes related to net share settlement of restricted stock units not yet paid	164	0
Series G Three Redeemable Convertible Preferred Stock [Member]
Supplemental disclosure of noncash investing and financing activities
Issuance of Series	3,809	2,738
Series G Four Redeemable Convertible Preferred Stock [Member]
Supplemental disclosure of noncash investing and financing activities
Issuance of Series	$ 611	$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock, Common Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	IPO [Member]	Excercise Of Warrants [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] IPO [Member]	Additional Paid-in Capital [Member] Excercise Of Warrants [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Redeemable Convertible Preferred Stock [Member]	Redeemable Convertible Preferred Stock [Member] Common Stock [Member]	Redeemable Convertible Preferred Stock [Member] Common Stock [Member] Series G-3 Preferred Stock [Member]	Redeemable Convertible Preferred Stock [Member] Common Stock [Member] Series G-5 Preferred Stock [Member]	Redeemable Convertible Preferred Stock [Member] Common Stock [Member] Series G-4 Preferred Stock [Member]	Class A Voting Stock [Member]	Class A Voting Stock [Member] Common Stock [Member]	Class A Voting Stock [Member] Common Stock [Member] IPO [Member]	Class A Voting Stock [Member] Common Stock [Member] Excercise Of Warrants [Member]	Class B Voting Stock [Member] Common Stock [Member]	Class B Voting Stock [Member] Common Stock [Member] Excercise Of Warrants [Member]	Non-voting Common Stock [Member] Common Stock [Member]
Beginning Balance, Shares at Dec. 31, 2022											62,692,927
Beginning Balance at Dec. 31, 2022											$ 1,026,143
Beginning Balance, Shares at Dec. 31, 2022				0												58,367,961					4,932,415
Beginning Balance at Dec. 31, 2022	$ (1,129,027)				$ 9,251			$ (1,138,302)	$ 18							$ 6					$ 0
Issuance of Series Preferred Stock												$ 2,738
Issuance of Series Preferred Stock, Shares												47,781
Foreign currency translation adjustment	25								25
Repurchase of Non-voting Common Stock	(3,602)			$ (3,602)
Repurchase of Non-voting Common Stock, Shares				(145,466)
Common stock issued in connection with business combination	4,305				4,305																$ 0
Common stock issued in connection with business combination, Shares																					130,874
Dividends											13,980
Dividends	(21,566)							(21,566)
Net loss	(110,209)							(110,209)
Ending Balance at Jun. 30, 2023	(1,260,074)			$ (3,602)	13,556			(1,270,077)	43							$ 6			$ 0		$ 0
Ending Balance, Shares at Jun. 30, 2023				(145,466)												58,367,961			0		5,063,289
Ending Balance at Jun. 30, 2023											$ 1,042,861
Ending Balance, Shares at Jun. 30, 2023											62,740,708
Beginning Balance, Shares at Mar. 31, 2023											62,740,708
Beginning Balance at Mar. 31, 2023											$ 1,034,321
Beginning Balance, Shares at Mar. 31, 2023				(145,466)												58,367,961			0		5,063,289
Beginning Balance at Mar. 31, 2023	(1,193,398)			$ (3,602)	13,556			(1,203,348)	(10)							$ 6			$ 0		$ 0
Foreign currency translation adjustment	53								53
Dividends											8,540
Dividends	(10,897)							(10,897)
Net loss	(55,832)							(55,832)
Ending Balance at Jun. 30, 2023	$ (1,260,074)			$ (3,602)	13,556			(1,270,077)	43							$ 6			$ 0		$ 0
Ending Balance, Shares at Jun. 30, 2023				(145,466)												58,367,961			0		5,063,289
Ending Balance at Jun. 30, 2023											$ 1,042,861
Ending Balance, Shares at Jun. 30, 2023											62,740,708
Beginning Balance, Shares at Dec. 31, 2023	63,525,953									63,525,953	63,525,953
Beginning Balance at Dec. 31, 2023											$ 1,105,543
Beginning Balance, Shares at Dec. 31, 2023				(145,466)												58,367,961					5,205,802
Beginning Balance at Dec. 31, 2023	$ (1,382,163)			$ (3,602)	18,345			(1,396,917)	5							$ 6					$ 0
Issuance of Series Preferred Stock												$ 3,809	$ 199,750	$ 611
Issuance of Series Preferred Stock, Shares												66,465	3,489,981	10,666
Foreign currency translation adjustment	(99)								(99)
Common stock issued in connection with business combination	344				344																$ 0
Common stock issued in connection with business combination, Shares																					9,141
Issuance of common stock upon settlement of restricted stock units, net	(70,082)				(70,082)											$ 0
Issuance of common stock upon settlement of restricted stock units, net (Shares)																2,651,848
Issuance of common stock		$ 369,604	$ (173)			$ 369,603	$ (173)										$ 1	$ 0		$ 0
Issuance of common stock (Shares)																	11,100,000	109,459
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering (Shares)											(67,093,065)
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering											$ (1,343,382)
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering	1,348,809				1,357,562			(8,761)								$ 7			$ 1
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering (Shares)																71,976,178			5,043,789
Conversion of non-voting common stock to Class A common stock	0				(1)											$ 1					$ 0
Conversion of non-voting common stock to Class A common stock (Shares)																5,069,477					(5,214,943)
Stock-based compensation expense	488,313				488,313
Dividends											33,669
Dividends	(39,347)							(39,347)
Net loss	(616,955)							(616,955)
Ending Balance at Jun. 30, 2024	98,251			$ (3,602)	2,163,911			(2,061,980)	(94)							$ 15			$ 1		$ 0
Ending Balance, Shares at Jun. 30, 2024				(145,466)												149,274,923			5,043,789		0
Ending Balance at Jun. 30, 2024											$ 0
Ending Balance, Shares at Jun. 30, 2024										0	0
Beginning Balance, Shares at Mar. 31, 2024											63,603,084
Beginning Balance at Mar. 31, 2024											$ 1,134,802
Beginning Balance, Shares at Mar. 31, 2024				(145,466)												58,367,961			0		5,214,943
Beginning Balance at Mar. 31, 2024	(1,474,425)			$ (3,602)	18,689			(1,489,467)	(51)							$ 6			$ 0		$ 0
Issuance of Series Preferred Stock													$ 199,750
Issuance of Series Preferred Stock, Shares													3,489,981
Foreign currency translation adjustment	(43)								(43)
Issuance of common stock upon settlement of restricted stock units, net	(70,082)				(70,082)											$ 0
Issuance of common stock upon settlement of restricted stock units, net (Shares)																2,651,848
Issuance of common stock		$ 369,604	$ (173)			$ 369,603	$ (173)										$ 1	$ 0
Issuance of common stock (Shares)																	11,100,000	109,459
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering (Shares)											(67,093,065)				71,976,178
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering											$ (1,343,382)
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering	1,348,809				1,357,562			(8,761)								$ 7			$ 1
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering (Shares)																71,976,178			5,043,789
Conversion of non-voting common stock to Class A common stock	0				(1)											$ 1					$ 0
Conversion of non-voting common stock to Class A common stock (Shares)																5,069,477					(5,214,943)
Stock-based compensation expense	488,313				488,313
Dividends											8,830
Dividends	(11,540)							(11,540)
Net loss	(552,212)							(552,212)
Ending Balance at Jun. 30, 2024	$ 98,251			$ (3,602)	$ 2,163,911			$ (2,061,980)	$ (94)							$ 15			$ 1		$ 0
Ending Balance, Shares at Jun. 30, 2024				(145,466)												149,274,923			5,043,789		0
Ending Balance at Jun. 30, 2024											$ 0
Ending Balance, Shares at Jun. 30, 2024										0	0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (552,212)	$ (55,832)	$ (616,955)	$ (110,209)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2024 shares
Eric Lefkofsky [Member]
Trading Arrangements, by Individual
Name	Eric Lefkofsky
Title	Chief Executive Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 14, 2024
Rule 10b5-1 Arrangement Terminated	true	[1],[2]
Termination Date	June 18, 2025
Aggregate Available	2,000,000	[2]
Ryan Fukushima [Member]
Trading Arrangements, by Individual
Name	Ryan Fukushima
Title	Chief Operating Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 14, 2024
Rule 10b5-1 Arrangement Terminated	true	[1],[2]
Termination Date	June 30, 2025
Aggregate Available	240,000
Erik Phelps [Member]
Trading Arrangements, by Individual
Name	Erik Phelps
Title	Executive Vice President
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 14, 2024
Rule 10b5-1 Arrangement Terminated	true	[1],[2]
Termination Date	June 30, 2025
Aggregate Available	0	[3]
Andrew Polovin [Member]
Trading Arrangements, by Individual
Name	Andrew Polovin
Title	Executive Vice President
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 14, 2024
Rule 10b5-1 Arrangement Terminated	true	[1],[2]
Termination Date	June 30, 2025
Aggregate Available	0	[4]
James Rogers [Member]
Trading Arrangements, by Individual
Name	James Rogers
Title	Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 14, 2024
Rule 10b5-1 Arrangement Terminated	true	[1],[2]
Termination Date	June 15, 2025
Aggregate Available	0	[4]
Ryan Bartolucci [Member]
Trading Arrangements, by Individual
Name	Ryan Bartolucci
Title	Chief Accounting Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 14, 2024
Rule 10b5-1 Arrangement Terminated	true	[1],[2]
Termination Date	June 30, 2025
Aggregate Available	0	[4]
[1]Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.[2]Represents the adoption of a Rule 10b5-1 trading plan by each of Blue Media, LLC and Gray Media, LLC, each an entity controlled by Mr. Lefkofsky, providing for the sale of up to 1,600,000 shares of Class A common stock held by Blue Media, LLC and up to 400,000 shares of Class A common stock held by Gray Media, LLC.[3]This Rule 10b5-1 trading plan provides for sales of up to approximately 94.8% (calculated on a weighted-average basis) of the net number of shares received upon vesting of an aggregate of 158,418 RSUs, after giving effect to the withholding or sale of a portion of such shares to satisfy tax withholding obligations. Accordingly, the aggregate maximum number of shares that may be sold pursuant to this trading arrangement is dependent on the amount of tax withholding required upon the vesting of RSUs, and, therefore, is indeterminable at this time.[4]This Rule 10b5-1 trading plan provides for sales of up to 100% of the net number of shares received upon vesting of an aggregate of 176,447 RSUs with respect to Mr. Polovin, 161,972 RSUs with respect to Mr. Rogers and 35,013 RSUs with respect to Mr. Bartolucci, after giving effect to the withholding or sale of a portion of such shares to satisfy tax withholding obligations. Accordingly, the aggregate maximum number of shares that may be sold pursuant to this trading arrangement is dependent on the amount of tax withholding required upon the vesting of RSUs, and, therefore, is indeterminable at this time.

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. DESCRIPTION OF BUSINESS Company Information Tempus AI, Inc., together with the subsidiaries through which it conducts business (the “Company”), is a healthcare technology company focused on bringing artificial intelligence and machine learning to healthcare in order to improve the care of patients across multiple diseases. The Company combines the results of laboratory tests with other multimodal datasets to improve patient care by supporting all parties in the healthcare ecosystem, including physicians, researchers, payers, and pharmaceutical companies. The Company primarily derives revenue from selling comprehensive genetic testing to physicians and large academic research institutions, licensing data to third parties, matching patients to clinical trials, and related services. The Company, based in Chicago, Illinois, was founded by Eric P. Lefkofsky, the Company’s CEO and Executive Chairman, and evolved from a business Mr. Lefkofsky founded called Bioin. Bioin originally was established as a limited liability company. Effective September 21, 2015, Bioin converted its legal form to a corporation organized and existing under the General Corporation Law of the State of Delaware. Bioin subsequently changed its legal name to Tempus Health, Inc. in September 2015, to Tempus Labs, Inc. in October 2016 and to Tempus AI, Inc. in December 2023. Initial Public Offering On June 13, 2024, the Company’s registration statement relating to its commissions In connection with the closing of the IPO, all shares of the Company’s then-outstanding redeemable convertible preferred stock, other than the Company’s Series B redeemable convertible preferred stock, converted into an aggregate of shares of Class A common stock. The Company’s Series B redeemable convertible preferred stock converted on a one-for-one basis into an aggregate of shares of Class B common stock. Subsequently, shares of Class B common stock were automatically converted into shares of Class A common stock, such that there are shares of Class B common stock outstanding immediately following the IPO. The Company issued an additional shares of Class A common stock pursuant to a separate agreement with an investor in the Series G-3 convertible preferred stock. As of June 16, 2024, the Company’s redeemable convertible preferred stock had accrued $188.2 million of unpaid dividends, which were paid in 5,098,799 shares of Class A common stock at the closing of the IPO. Outstanding shares of non-voting common stock were converted on a one-for-one basis into 5,069,477 shares of Class A common stock. The restricted stock units (“RSUs”) granted to employees pursuant to the Company’s 2015 Plan are subject to two vesting conditions. The first is a time-based component. The second vesting condition is the occurrence of a liquidity event. The liquidity event condition related to these awards was satisfied upon the IPO and, as a result, the Company recognized $488.3 million of stock-based compensation expense for the six months ended June 30, 2024 The Company issued 109,459 shares of Class A common stock upon the automatic net exercise of a warrant issued to Allen & Company LLC (“Allen”), as further described in Note 8. In connection with the IPO, the Company amended and restated its certificate of incorporation (the “Restated Certificate”), under which authorized capital stock consists of shares of Class A common stock, shares of Class B common stock, and shares of preferred stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The condensed consolidated financial statements include the accounts of Tempus AI, Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial information and include the assets, liabilities, revenue and expenses of all wholly owned subsidiaries. Investments in unconsolidated entities in which the Company does not have a controlling financial interest, but has the ability to exercise significant influence, are accounted for under the equity method of accounting. Investments in unconsolidated entities in which the Company is not able to exercise significant influence are accounted for under the cost method of accounting. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been omitted. Accordingly, the unaudited interim condensed conde nsed In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of June 30, 2024 and its results of operations for the three and six months ended June 30, 2024 and 2023, and cash flows for the six months ended June 30, 2024 and 2023. The condensed consolidated balance sheet at December 31, 2023, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The Company believes that its existing cash and cash equivalents and marketable equity securities at June 30, 2024 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year from the date of issuance. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company’s cost structure. Future capital requirements will depend on many factors, including the timing and extent of spending on research and development activities and growth related expenditures. Other than described below, there have been no changes to the Company’s significant accounting policies described in the “Notes to the Consolidated Financial Statements” included in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Prospectus that have had a material impact on the Company’s consolidated financial statements and accompanying notes. Reclassification Certain prior year amounts have been reclassified for consistency with the current year presentation. Emerging Growth Company The Company is an “emerging growth company” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging condensed Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities, revenue and expenses, and the related disclosures of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. The most significant estimates are related to revenue, accounts receivable, stock-based compensation, operating lease liabilities, and the useful lives of property, equipment and intangible assets. Actual results could differ from those estimates. Net Loss Per Share Attributable to Common Stockholders Basic and diluted net loss per share attributable to common stockholders is presented in conformity with two-class two-class Deferred Offering Costs Deferred offering costs consist primarily of accounting, legal, and other fees related to the IPO. The Company had $ million of deferred offering costs as of December 31, 2023. Prior to the IPO, deferred offering costs were capitalized on the consolidated balance sheets. Upon the consummation of the IPO, $ million of deferred offering costs were reclassified into additional paid-in capital as an offset against IPO proceeds. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which provides enhanced disclosures about significant segment expenses. The standard also enhances interim disclosure requirements and provides new segment disclosure requirements for entities with a single reportable segment. The standard is effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods presented. Early adoption is permitted. The Company is currently evaluating the effect that this guidance will have on the consolidated financial statements and related disclosures. In 2023-09, 2023-09

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2024
Revenue Recognition [Abstract]
Revenue Recognition	3. REVENUE RECOGNITION The Company derives revenue from selling lab services (“Genomics”) to physicians, academic research institutions, and other parties. The Company also derives revenue from the commercialization of data generated in the lab (“Data and services”) through the licensing of de-identified The Company accounts for revenue in accordance with Financial Accounting Standards Board (“FASB”) ASC 606 Revenue from Contracts with Customers Disaggregation of Revenue The Company provides disaggregation of revenue based on Genomics and Data and services on the condensed consolidated statements of operations and comprehensive loss, as it believes these best depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. Genomics The Company generally recognizes revenue for its Genomics product offering when it has met its performance obligation relating to an order. The Company has determined its sole performance obligation to be the delivery of the testing results to the ordering party. The Company receives payments from Medicare, Medicaid, and commercial insurance for clinical orders and directly from research institutions, pharmaceutical companies or other third parties for direct bill orders. The Company recognized Genomics revenue of $112.3 million and $91.9 million for the three months ended June 30, 2024 and 2023, respectively. The Company recognized Genomics revenue of $214.9 million and $174.0 million for the six months ended June 30, 2024 and 2023, respectively. For clinical orders from Medicare, Medicaid, and commercial insurance, the Company determines transaction price by reducing the standard charge by the estimated effects of any variable consideration, such as contractual allowance and implicit price concessions. The Company estimates the contractual allowances and implicit price concessions based on historical collections in relation to established rates, as well as known current or anticipated reimbursement trends not reflected in the historical data. Estimates are inclusive of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. The Company monitors the estimated amount to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Payment is typically due after the claim has been processed by the payer, generally 30-120 For direct bill orders from research institutions, pharmaceutical companies, or other third parties, the Company determines the transaction prices based on established contractual rates with the customer, net of any applicable discounts. Payment is typically due between 30 and 60 days following the date of invoice. The Company recognized Genomics revenue for direct bill orders of $10.6 million and $7.5 million for the three months ended June 30, 2024 and 2023, respectively and Data and services Data and services revenue primarily represents data licensing and clinical trial services that the Company provides to pharmaceutical and biotechnology companies. The Company’s arrangements with these customers often have terms that span multiple years. However, these contracts generally also include customer opt-in Insights The Company’s Insights product consists primarily of licensing and analysis of de-identified de-identified The Company has determined that the delivery of de-identified • Data licensing on a one-time • Multi-year data subscriptions de-identified • Analytical services and other services • Enhanced Lens application subscription services software-as-a-service The Company recognized revenue from Insights products of $40.7 million and $29.1 million for the three months ended June 30, 2024 and 2023, respectivel y and Trials The Company’s Trials product includes TIME clinical trial matching services and other clinical trial services. TIME consists primarily of matching patients to clinical trial sponsors of a potential match. To the extent the contract requires, the Company may also assist in opening the clinical trial site and enrolling the patient in the clinical trial. The Company has determined that, depending on the type of agreement, the performance obligation of these contracts is the delivery of a notification or the enrollment of a patient in a clinical trial. As such, revenue is recognized upon one of the following: delivery of a notification to the physician alerting them to a clinical trial match, or once a patient is enrolled in a trial. Concurrently, the customer, which is the clinical trial sponsor, also receives notification from the Company to establish the performance obligations delivered or fulfilled for the billing period. In addition to TIME, the Company provides other clinical trial services conducting or supporting studies. Tempus Compass LLC, a subsidiary of the Company, is a contract research organization, or CRO, which manages and executes early and late-stage clinical trials, primarily in oncology. Contracts for clinical trial services can take the form of fee-for-service Fee-for-service out-of-pocket The Company recognized revenue from Trials products of $10.5 million and $10.6 million for the three months ended June 30, 2024 and 2023, respectively and For Insights and Trials arrangements, pricing is fixed and the Company may be compensated through a combination of an upfront payment and performance-based, non-refundable non-for-profits, Multi-year contract performance obligations The Company has limited multi-year contracts that do not contain early termination or customer opt-in $ % % remaining performance obligations as revenue in years two, three, and four, respectively. Contract Assets Timing of revenue recognition may differ from the timing of invoicing to customers. Certain performance obligations may require payment before delivery of the service to the customer. The Company recognizes contract assets when the Company has an unconditional right to payment, and when revenues earned on a contract exceeds the billings. Contract assets are presented under accounts receivable, net. Accounts receivable as of June 30, 2024 and December 31, 2023 included contract assets During the fourth quarter of 2021, and in conjunction with the signing of a November 2021 Master Services Agreement (“the MSA”) with customer AstraZeneca AB (“AstraZeneca”), the Company recognized a contract asset for consideration payable concurrent with the issuance of the common stock warrant in accordance with ASC 606. The contract asset was initially measured equal to the initial fair value of the warrant liability based on the authoritative guidance under FASB ASC 718 Compensation—Stock Compensation The following summarizes the warrant contract asset presentation as of June 30, 2024 and December 31, 2023 (in thousands): June 30, 2024 December 31, 2023 Prepaid expenses and other current assets $ 4,843 $ 4,843 Warrant contract asset, less current portion 19,077 21,499 Total warrant contract asset $ 23,920 $ 26,342 In November 2023, the Company entered into a Commercialization and Reference Laboratory Agreement with Personalis, Inc. (“Personalis”). The Company will pay up to $12.0 million to Personalis over three years as certain milestones are met, $7.0 million of which has been paid as of June 30, 2024. These payments are treated as contract assets and amortized into revenue over the life of the contract. In addition, as consideration for the Company’s obligations to Personalis under the Commercialization and Reference Laboratory Agreement, Personalis issued certain warrants to the Company to purchase up to an aggregate of 9,218,800 shares of Personalis’ common stock, up to 4,609,400 of which are exercisable for cash at any time prior to December 31, 2024 at an exercise price of $1.50 per share, and up to 4,609,400 of which are exercisable for cash at any time prior to December 31, 2025 at an exercise price of $2.50 per share. Contract asset balances are offset by deferred revenue generated from issuance of the Personalis warrant asset. As of June 30, 2024 and December 31, 2023, there was $1.1 million and Deferred Revenue Deferred revenue consists of billings or cash received for services in advance of revenue recognition and is recognized as revenue when all the Company’s revenue recognition criteria are met. The deferred revenue balance is influenced primarily by upfront contractual payments from the Company’s Data and Services product offerings and timing of delivery of the Company’s de-identified non-current.

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2024
Business Combinations [Abstract]
Business Combinations	4. BUSINESS COMBINATIONS SEngine On October 3, 2023, the Company acquired all of the issued and outstanding interests of SEngine Precision Medicine LLC (“SEngine”), a Delaware limited liability company. The acquisition gives the Company access to SEngine’s meaningful organoid repository, advanced bioinformatics capabilities, and PARIS test platform. The acquisition resulted in goodwill of $9.6 million. The aggregate acquisition date fair value of consideration for the SEngine acquisition totaled $9.9 million. Consideration consisted non-voting non-voting non-voting Mpirik On March 8, 2023, the Company acquired all of the issued and outstanding interests of Mpirik, Inc. (“Mpirik”), a cardiology-focused healthcare technology company specializing in data-driven patient screening, automated care coordination, and clinical research. Mpirik’s platform adds to the Company’s existing portfolio to address the way heart disease is detected, diagnosed, and treated, further expanding Tempus’s cardiology business. The acquisition resulted in goodwill of $10.6 million. The aggregate acquisition date fair value of consideration for the Mpirik acquisition totaled $9.7 million. Consideration was made up of $4.6 million of non-voting non-voting Cash consideration of $4.7 million is net of a $0.3 million net working capital adjustment. In accordance with the terms of the agreement, the securityholders of the acquired business w ere ed d as ed performance stock units to certain retained Mpirik employees on the closing date of the acquisition. In July 2023, the Company’s board of directors approved the removal of the performance-vesting condition, following which performance stock units are treated as restricted stock units. Arterys On October 3, 2022, the Company acquired Arterys, Inc. (“Arterys”), a company that provides a platform to derive insights from radiology medical imagines to improve diagnostic decision-making, efficiency, and productivity across multiple disease areas, which resulted in goodwill of $11.1 million. The aggregate acquisition date fair value of consideration for the Arterys acquisition totaled $8.3 million, net of cash acquired of $0.3 million. Consideration was made up of $4.9 million of non-voting million of cash. Cash consideration

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	5. BALANCE SHEET COMPONENTS Property and Equipment, net The following summarizes property and equipment, net as of June 30, 2024 and December 31, 2023 (in thousands): June 30, 2024 December 31, 2023 Equipment $ 101,631 $ 91,656 Leasehold improvements 44,000 42,433 Furniture and fixtures 6,633 6,633 Total property and equipment, gross 152,264 140,722 Less: accumulated depreciation (91,725 ) (79,041 ) Property and equipment, net $ 60,539 $ 61,681 Depreciation expense on property and equipment is classified as follows in the accompanying c ondensed Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Cost of revenue, genomics $ 3,293 $ 3,222 $ 6,674 $ 6,363 Selling, general and administrative costs 3,122 1,972 6,010 3,891 Total depreciation $ 6,415 $ 5,194 $ 12,684 $ 10,254 Accrued Expenses Accrued expenses as of June 30, 2024 and December 31, 2023, consist of the following (in thousands): June 30, 2024 December 31, 2023 Accrued compensation and employee benefits $ 18,532   $ 21,950 Accrued expenses 44,053 37,783 Accrued cloud storage costs 13,723 13,921 Interest payable 8,877 8,863 Total accrued expenses $ 85,185 $ 82,517

Goodwill and Intangibles

Goodwill and Intangibles	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangibles	6. GOODWILL AND INTANGIBLES Goodwill Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. There were no goodwill additions for the three months ended June 30, 2024 and 2023, or for the six months ended June 30, 2024. During the six months ended June 30, 2023, goodwill of $10.6 million was recorded in connection with the acquisition of Mpirik. The Company recorded no impairment loss during the three and six months ended June 30, 2024 and 2023. Intangible assets Intangible assets are initially recorded at their acquisition cost, or fair value if acquired as part of a business combination and amortized over their estimated useful lives. Intangible assets consist of a website domain, customer relationships and trade names acquired as part of a business combination, and licensed data acquired by entering into research collaboration agreements. In each license arrangement, the other party provides the Company with specified data, which currently is used primarily for research and development purposes but may also be licensed to third parties. The asset represents the Company’s right to use these datasets. The Company also recognizes a liability for the associated minimum payments that are presented within accrued data licensing fees. During the six months ended million in licensed data related to de-identified In January 2023, the Company amended a data licensing agreement, which reduced the future data license payments the Company owes in exchange for waiving exclusivity rights on the licensed data. The Company remeasured the related licensed data intangible asset to fair value, which resulted in an impairment of $7.4 million recorded in Research and development during the six mon t The following table summarizes intangible assets as of June 30, 2024 and December 31, 2023 (in thousands): June 30, 2024 December 31, 2023 Gross Amount Accumulated Net Gross Amount Accumulated Net Customer relationships $ 20,550 $ 13,913 $ 6,637 $ 20,550 $ 12,219 $ 8,331 Licensed data 19,321 14,868 4,453 19,321 11,469 7,852 Website domain 19 —  19 19 —  19 Trade names 8,000 2,857 5,143 8,000 2,286 5,714 $ 47,891 $ 31,638 $ 16,252 $ 47,890 $ 25,974 $ 21,916 Amortization of intangible assets is recognized using the straight-line method over their estimated useful lives, which range from three the Company’s

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. COMMITMENTS AND CONTINGENCIES Legal Matters From time to time in the normal course of business, the Company may be subject to various legal matters such as threatened or pending claims or proceedings. There were no material such matters as of and for the three and six months ended June 30, 2024 and 2023.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Stockholders' Equity	8. STOCKHOLDERS’ EQUITY Common Stock Prior to the IPO, the Company had authorized two classes of common stock, voting and non-voting. In March non-voting G-5 Class A common stock and Class B common stock are collectively referred to as “Common Stock” throughout the notes to these unaudited interim con densed The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting. Each share of Class A common stock is entitled to one vote per share and each share of Class B common stock is entitled to thirty votes per share. Prior to the IPO, the Company also had shares of non-voting common stock authorized and outstanding, which were not entitled to any voting rights. Following the IPO, no shares of non-voting common stock are authorized or outstanding. Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. Under the Restated Certificate, any holder’s shares of Class B common stock will convert automatically into Class A common one-to-one anniversary of the filing of the Restated Certificate, which was filed with the Secretary of State of the State of Delaware on June 17, 2024; (3) the date on which Mr. Lefkofsky is no longer providing services to the Company as an executive officer or member of the board of directors; and (4) the trading day that is no less than Once transferred and converted into Class A common stock, the Class B common stock may not be reissued. The Company issues stock-based awards to its employees in the form of stock options, restricted stock units, performance stock units and restricted stock, all of which have the potential to increase the outstanding shares of common stock in the future (see Note 10, Stock-Based Compensation). Upon any liquidation, dissolution, or winding-up, Common Stock Warrant In connection with the MSA with AstraZeneca, the Company granted AstraZeneca warrants to purchase million in shares of the Company’s Class A common stock at an exercise price equal to the IPO price of $37.00 per share. The number of shares of Class A common stock issuable upon exercise of the warrant is 2,702,703, based on the IPO price of $37.00 per share. The warrant will be automatically cancelled and terminated for no consideration in the event AstraZeneca declines to extend its financial commitment before December 31, 2024. If AstraZeneca exercises the warrant, AstraZeneca will be required to increase its minimum commitment under the MSA from $220 million to $320 million through December 2028. On December 8, 2023, the Company issued Allen a warrant to purchase The warrant was issued as compensation for Allen’s assistance with the issuance of the Company’s Series G-4 preferred stock, and as such has been treated as an issuance cost and presented net of proceeds from Series G-4 preferred stock in Convertible redeemable preferred stock on the Company’s consolidated balance sheet. In connection with the IPO, the Company issued shares of Class A common stock upon the net exercise of the warrant. Treasury Stock In January 2023, the Company repurchased 145,466 shares of non-voting

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2024
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock	9. REDEEMABLE CONVERTIBLE PREFERRED STOCK In January 2023, the Company issued 47,781 shares of Series G-3 paid-in-kind In January 2024, the Company issued 66,465 shares of Series G-3 G-4 paid-in-kind In October 2023, the Company issued 785,245 shares of Series G-4 convertible preferred stock (“Series G-4 Preferred”) for aggregate proceeds of $45.0 million. Each share ha d ld Preferred In April 2024, the Company issued 3,489,981 shares of Series G-5 G-5 In connection with the IPO, all of the Company’s then-outstanding shares of redeemable convertible preferred stock and accrued but unpaid dividends were automatically converted into Redeemable convertible preferred stock outstanding as of December 31, 2023 consisted of the following (in thousands, except share amounts): As of December 31, 2023 Series Year Shares Liquidation Carrying Preferred Issued Authorized Outstanding Amount Value Series A 2015 10,000,000 10,000,000 $ 10,500 $ 10,000 Series B 2016 5,374,899 5,374,899 10,500 10,000 Series B-1 2016 2,500,000 2,500,000 10,500 10,000 Series B-2 2017 4,191,173 4,191,173 31,500 30,000 Series C 2017 9,779,403 9,779,403 86,757 70,000 Series D 2018 8,534,330 8,534,330 105,107 104,145 Series E 2018 6,630,905 6,630,905 151,621 151,621 Series F 2019 8,077,674 8,077,674 261,722 261,722 Series G 2020 2,537,290 2,537,290 119,928 119,928 Series G-2* 2020/2021 3,453,139 3,453,139 197,889 197,889 Series G-3** 2022/2023 4,362,476 1,661,895 98,891 95,238 Series G-4** 2023 4,362,476 785,245 45,514 45,000 Total convertible preferred stock 69,803,765 63,525,953 1,130,429 1,105,543 * Excludes amounts related to the conversion of convertible note ** Excludes amounts related to embedded conversion features

Stock-based compensation

Stock-based compensation	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based compensation	10. STOCK-BASED COMPENSATION 2015 Stock Plan In 2015, the Company adopted the Tempus AI, Inc. 2015 Stock Plan (the “2015 Plan”), which has been amended and restated numerous times to increase the aggregate shares authorized to be issued to employees, consultants, and directors of the Company. As of December 31, 2023, there were shares authorized under the 2015 Plan. On January 18, 2023, the Company approved a two-year extension of the expiration date for active employees whose RSUs expire either in 2023 or 2024. The Company accounted for the extension as a stock compensation modification, which resulted in an increase in unrecognized compensation cost of $47.5 million and $35.3 million for the three and six months ended June 30, 2024 and 2023, respectively. During the three and six months ended June 30, 2024, the Company granted 1,647,906 and 1,933,606 RSUs, respectively. Restricted Stock Units The RSUs granted under the 2015 Plan are subject to two vesting conditions. The first is a time-based component. The majority of the awards are eligible to vest over a four-year period, with 20% of the awards being eligible to vest after one year and the remaining awards becoming eligible to vest on a quarterly basis thereafter. The second vesting condition is the occurrence of a liquidity event, as defined in the grant agreement, which was satisifed in connection with the IPO. The table below summarizes restricted stock unit activity under the 2015 Plan for the six months ended June 30, 2024: Restricted Stock Units Weighted - Grant Date Fair Value Unvested at December 31, 2023 20,788,500 $ 26.47 Granted 1,933,606 $ 37.59 Vested and settled (4,563,164 ) $ 11.93 Vested and not yet settled (10,870,652 ) $ 24.46 Forfeited (457,785 ) $ 25.58 Expired (147,376 ) $ 0.28 Unvested at June 30, 2024 6,683,129 $ 36.77 Stock-based compensation is classified as follows in the accompanying condensed Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Cost of revenues, genomics $ 11,327 $ —  $ 11,327 $ —  Cost of revenues, data and services 7,229 —  7,229 —  Technology research and development 50,434 —  50,434 —  Research and development 42,233 —  42,233 —  Selling, general and administrative 377,090 —  377,090 —  Total stock-based compensation $ 488,313 $ —  $ 488,313 $ —  Total unrecognized stock-based compensation expense related to RSUs was $ million as years. No further grants will be made under the 2015 Plan. 2024 Equity Incentive Plan In February 2024, the Company’s board of directors adopted, and in April 2024, the Company’s stockholders approved, the 2024 Equity Incentive Plan (the “2024 Plan”), which became effective in connection with the IPO in June 2024. The 2024 Plan provides for the grant of incentive stock options, (“ISOs”) nonstatutory stock options (“NSOs”), stock appreciation rights, RSUs, restricted stock unit awards (“RSAs”), performance-based awards (“PSUs”) and other awards. The maximum number of shares of Class A common stock that may be issued under the 2024 Plan is shares of the Company’s Class A common stock and will automatically increase on January 1 of each year, beginning on January 1, 2025 and continuing through and including in an amount equal to either (i) a number of shares of the Company’s Class A common stock (the “Evergreen Increase”), such that the sum of (x) the remaining number of shares available under the 2024 Plan and (y) the Evergreen Increase is equal to % of the total number of shares of common stock (both Class A and Class B) outstanding on December 31 of the preceding calendar year, or (ii) a lesser number of shares determined by the Company’s board of directors prior to the applicable January 1. The maximum number of shares that may be issued upon the exercise of ISOs under the 2024 Plan is shares.

Debt

Debt	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Debt	11. DEBT Term Loan Facility On September 22, 2022, the Company entered into a Credit Agreement with Ares Capital Corporation (“Ares”) for a senior secured loan (the “Term Loan Facility”) in the amount of $175 million, less original issue discount of $4.4 million and deferred financing fees of $2.6 million. On April 25, 2023, the Company entered into an amendment to the Credit Agreement, which was accounted for as a debt modification. The amendment to the Credit Agreement increased the Term Loan Facility by an aggregate principal amount of $50 million, less original issue discount of $1.3 million and increased the interest rate on the Term Loan Facility by 25 basis points. On October 11, 2023, the Company signed a second amendment to its Credit Agreement with Ares which provided an additional $35.0 million in term debt. The Company received $34.1 million in cash, which is the aggregate principal amount of $35.0 million less original issue discount of $0.9 million. Terms of the second amendment are consistent with existing terms of the Credit Agreement. The proceeds of the Term Loan Facility will be used for working capital and general corporate purposes, to finance growth initiatives, to pay for operating expenses, and to pay the related transaction costs After the first three months from the effective date, each quarter, the Company has the option to convert the borrowing type to either a Base Rate Borrowing, which bears interest based on a Base Rate, defined as the greatest of the (a) the “Prime Rate” appearing the “Money Rates” section of the Wall Street Journal or another national publication selected by the Agent, (b) the Federal Funds Rate plus 0.50%, (c) Term SOFR for a one-month (i) the sum of the Base Rate plus an Applicable Rate of 4% per annum plus 3.25% per annum paid in-kind (ii) the Base Rate plus an Applicable Rate of 6.25% per annum (iii) the sum of the Term SOFR for the interest period plus an Applicable rate of 5% per annum plus 3.25% per annum paid in-kind (iv) the Term SOFR for the interest period in effect plus the Applicable Rate of 7.25% per annum In addition, the Term Loan st All obligations under the Term Loan Facility are guaranteed by the Company and secured by substantially all of the assets of the Company. The original issue discount of $6.5 million and deferred financing fees of $2.6 million are amortized over the term of the underlying debt and unamortized amounts have been offset against long-term debt in the consolidated balance sheets. As of June 30, 2024 and December 31, 2023, the unamortized original issue discount was $4.5 million and $5.1 million, respectively, and the unamortized deferred financing fees were $1.6 million and $1.9 million, respectively. Through June 30, 2024, the Company has not made any principal repayments on the Term Loan Facility. Through June 30, 2024, the Company made $13.9 million in interest payments. As of June 30, 2024, the interest rate on the Term Loan Facility was 10.3%. As of June 30, 2023, the interest rate on the $175 million originally borrowed under Term Loan Facility was 9.89% and 10.07% on the $50 million borrowed under the amended Credit Agreement. The Company recognized interest expense of million related to the Term Loan Facility during the three and six months ended June 30, 2024, respectively. The Company recognized interest expense of million related to the Term Loan Facility during the three and six months ended June 30, 2023, respectively. Convertible Promissory Note On June 22, 2020, in connection with entry into an agreement for use of Google LLC’s, or Google’s, Google Cloud Platform, the Company issued Google a convertible promissory note, or the Note, in the original principal amount of $330.0 million. On November 19, 2020, in connection with Series G-2 G-2 The amended and restated Note, or the Amended Note, has a principal amount of $250.0 million, and bears interest at the rate set forth therein. The principal amount is automatically reduced each year based on a formula taking into account the aggregate value of the Google Cloud Platform services used by the Company. The Company accounts for the principal reductions as an offset to its cloud and compute spend within selling, general and administrative in its condensed c s o c l If the Amended Note is outstanding at the maturity date, Google may, at its option, convert the then outstanding principal amount and interest accrued under the Amended Note into a number of shares of the Company’s Class A common stock equal to the quotient obtained by dividing (1) the Outstanding Amount on the maturity date, by (2) the average of the last trading price on each trading day during the day period ending immediately prior to the maturity date. The Company concluded that one of the conversion features meets the definition of an embedded derivative that is required to be accounted for as a separate unit of accounting. The fair value of the embedded derivative is not material and was therefore not bifurcated. As such, upon issuance of the Note the Company recorded a promissory note of $330.0 million. The Company recognized interest expense of $3.7 million and $3.8 million during the three months ended June 30, 2024 and 2023, respectively. The company recognized interest expense of $7.3 million and $7.6 million during the six months ended June 30, 2024 and 2023, respectively.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	12. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS Basic net loss per share is calculated by dividing the net loss by the weighted average number of outstanding shares of Common Stock each period. The Company’s Class A common stock and Class B common stock share equally in distributed and undistributed earnings; therefore, no allocation to participating securities or dilutive securities is performed. Diluted net loss per share is calculated by giving effect to all potential dilutive Common Stock equivalents, which includes stock options, RSUs, RSAs, PSUs, and preferred stock. Because the Company incurred net losses each period, the basic and diluted calculations are the same. The Company used the if-converted The following table presents the calculation for basic and diluted net loss per share (in thousands, except share and per share data): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator: Net loss $ (552,212 ) $ (55,832 ) $ (616,955 ) $ (110,209 ) Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares (11,540 ) (10,897 ) (39,347 ) (21,566 ) Cumulative Undeclared Dividends on Series C preferred shares (668 ) (745 ) (1,174 ) (1,466 ) Net loss attributable to common stockholders $ (564,420 ) $ (67,474 ) $ (657,476 ) $ (133,241 ) Denominator: Weighted-average common shares outstanding, basic and diluted 82,325 63,286 72,930 63,257 Net loss per share attributable to common stockholders, basic and diluted $ (6.86 ) $ (1.07 ) $ (9.02 ) $ (2.11 ) The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share for each period, as the impact of including them would have been anti-dilutive. As disclosed in Note 8, the Company issued a warrant for $100 million in shares of the Company’s Class A common stock. As per the terms of th e As of June 30, 2024 2023 Stock options outstanding 210,000 210,000 AstraZeneca warrant 2,702,703 1,744,991 Mpirik holdback liability —  8,724 SEngine holdback liability 41,007 —  Sengine contingent consideration 35,000 —  Unvested RSUs 6,683,129 —  Total potentially dilutive shares 9,671,839 1,963,715 As disclosed in Note 10, the RSUs issued under the 2015 Plan include a triggering liquidation performance condition prior to vesting. As such, as of June 30, 2023, these are treated as contingently issuable shares and are excluded from potentially dilutive shares as the liquidation performance condition was not yet satisfied. As the liquidation performance condition was satisfied upon completion of the IPO, as of June 30, 2024, these shares are included in potentially dilutive shares. As disclosed in Note 11, contingent upon certain financing events, the Amended Note will be converted to shares at the holder’s option, based on the amount outstanding at the maturity date, which is subject to reduction based on services used by us prior to the maturity date. As such, these are treated as contingently issuable shares and will be excluded from potential dilutive impact. As disclosed in Note 9, the Company’s Series G-3 G-4 G-5

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	13. INCOME TAXES Accounting for income taxes for interim periods generally requires the provision for income taxes to be determined by applying an estimate of the annual effective tax rate for the full fiscal year to income or loss before income taxes, adjusted for discrete items, if any, for the reporting period. The Company updates its estimate of the annual effective tax rate each quarter and makes a cumulative adjustment in such period. Income tax expense (benefit) for the three and si x Due to the Company’s history of losses in the United States, a full valuation allowance on all of the Company’s deferred tax assets, including net operating loss carryforwards and other book versus tax differences, was maintained.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	14. FAIR VALUE MEASUREMENTS The carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, finance lease obligations, minimum royalties, accounts payable, and accrued expenses approximate fair value due to the short maturity of these instruments. The carrying amounts of the related party receivable, finance lease obligations, and minimum royalties approximate fair value because the interest rates used fluctuate with market interest rates or the fixed rates are based on current rates offered to the Company for debt with similar terms and maturities. The valuation methodologies used for the Company’s assets and liabilities measured at fair value and their classification in the valuation hierarchy are summarized below: Marketable equity securities During the three months ended June 30, 2024, the Company did not sell any shares of Recursion Class A common stock. During the six months ended June 30, 2024, the Company sold 1,725,902 shares of Recursion Class A common stock at a weighted average price of $13.38 for $23.1 million. Changes in fair value are recorded in earnings within other (expense) income, net on the condensed The following summarizes the portion of unrealized gains recorded during the three and six months ended June 30, 2024 that relate to marketable securities held as of June 30, 2024 (in thousands): Three Months Ended Six Months Ended June 30, 2024 June 30, 2024 Net (loss) gain during the period on marketable equity securities $ (3,705 ) $ 2,541 Less: Net gain recognized during the period on marketable equity securities sold during the period —  (6,081 ) Unrealized gain recognized during the period on marketable equity securities still held at the reporting date $ (3,705 ) $ (3,540 ) Contingent consideration $ million, contingent upon Mpirik reaching a revenue target of $ million for the twelve-month period ended December 31, 2023. See Note 4, Business Combinations, for further discussion of that acquisition. The Company is also subject to a contingent consideration arrangement of 35,000 additional shares of non-voting non-voting 4 Liabilities for contingent consideration are measured at fair value each reporting period, with the acquisition date fair value included as part of the consideration transferred in the related business combination and subsequent changes in fair value recorded in earnings within operating expense on the condensed non-voting Warrant asset Warrant liability The following table summarizes the assumptions used in the model as of June 30, 2024: Expected term (in years) 2.50 Risk-free interest rate 4.51 % Expected volatility 55.00 % Expected dividend yield 0.00 % The Company classifies the warrant liability as Level 3 due to the lack of relevant observable market data over fair value inputs such as the expected term. The Term Loan Facility and the Note were not recorded at fair value. The fair values of the Term Loan Facility and the Note approximated their carrying values as of June 30, 2024 and December 31, 2023. Estimates of the fair values of the Term Loan Facility and the Note are classified as Level 3 due to the lack of relevant observable market data over fair value inputs. The following tables summarize assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Fair Value Measurement at Reporting Date Using June 30, 2024 Quoted Price in (Level 1) Significant Other (Level 2) Significant Assets Marketable equity securities $ 11,255 $ 11,255 $ —  $ —  Warrant asset $ 2,300 $ —  $ 2,300 $ —  Liabilities Warrant liability $ 33,600 $ —  $ —  $ 33,600 Contingent consideration $ 940 $ 940 $ —  $ —  Fair Value Measurement at Reporting Date Using December 31, 2023 Quoted Price in Significant Other Significant Assets Marketable equity securities $ 31,807 $ 31,807 $ —  $ —  Warrant asset $ 10,000 $ —  $ 10,000 $ —  Liabilities Warrant liability $ 34,500 $ —  $ —  $ 34,500 Contingent consideration $ 775 $ —  $ —  $ 775 The following tables provide a reconciliation of the beginning and ending balances for the assets and liabilities measured at fair value using significant unobservable inputs (Level 3) (in thousands): Warrant Liability Contingent Balance at December 31, 2023 $ 34,500 $ 775 Change in fair value of warrant liability (900 ) —  Change in fair value of contingent consideration —  194 Transfer out of Level 3 —  (969 ) Balance at June 30, 2024 $ 33,600 $ —  Warrant Liability Contingent Balance at December 31, 2022 $ 42,500 $ —  Contingent consideration from Mpirik acquisition —  400 Change in fair value of warrant liability (5,700 ) —  Balance at June $ 36,800 $ 400 For the three months ended June 30, 2024 and 2023, the Company recognized a gain of $1.7 million and expense of $0.7 million, respectively, in other (expense) income, net due to the change in the fair value of warrant liability determined by Level 3 valuation techniques. For the six months ended June 30, 2024 and 2023, the Company recognized a gain of $0.9 million and $5.7 million, respectively, in other expense

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Parties	15. RELATED PARTIES In 2018, the Company received $1.5 million from a related party for assuming an office lease from such party. The liability is amortized through the right-of-use asset as a reduction of rent expense over the lease term. The Company had a remaining related liability of $0.7 million as of June 30, 2024 and December 31, 2023. The Company subleases a portion of office space to this related party on a month-to-month Strategic Investment On August 19, 2021, the Company entered into a related party arrangement with Pathos AI, Inc. (“Pathos”) for the purpose of furthering the commercialization efforts of drug development. Tempus received a warrant to purchase 23,456,790 shares, or approximately 19% of the current outstanding equity in Pathos, for $0.0125 per share. The warrant will automatically exercise upon a change of control (as defined therein) or upon an IPO of Pathos’ securities. The Company also has an optional exercise election window during the last 10 days of the 20 year term of the warrant agreement. Pursuant to this master agreement, the Company granted Pathos a limited, non-exclusive, non-transferable de-identified de-identified In 2022, the Company entered into two additional related party arrangements with Pathos for both sequencing and other data services. The Company recognized less than $0.3 million in revenue for both arrangements for both the three and six months ended June 30, 2024 and 2023. In 2023, the Company entered into an additional related party arrangement with Pathos for other data services. The Company recognized less than $0.1 million in revenue for both the three and six months ended June 30, 2024 and 2023. As of June 30, 2024 and December 31, 2023, there was no amount due to related parties. As of both .

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	16. SUBSEQUENT EVENTS Japan Joint Venture On May 18, 2024, the Company entered into a Joint Venture Agreement (the “Joint Venture Agreement”), by and among SoftBank Group Corporation (“SoftBank”), SoftBank Group Japan Corporation, the Company and Pegasos Corp. (the “Joint Venture”), pursuant to which the Joint Venture will engage in certain business activities in Japan similar to those conducted by the Company in the United States, including performing clinical sequencing, organizing patient data, and building a real world data business in Japan. The Joint Venture closed on July 18, 2024. The Company and SoftBank capitalized the Joint Venture with ¥30,000,000,000 (approximately $191.1 million 50% of the Joint Venture’s outstanding capital stock and board seats. In connection with entering into the Joint Venture Agreement, the Company entered into the following agreements with the Joint Venture: a Data License Agreement (the “Data License Agreement”), which became effective immediately upon signing the Joint Venture Agreement; an Intellectual Property License Agreement (the “IP License Agreement”) and a Services Agreement, each of which became effective on July 18, 2024 upon closing. Under the Data License Agreement, the Company granted the Joint Venture a limited, non-exclusive, transferable license with a limited right to sublicense certain de-identified data for certain specified uses solely in Japan. Under the Data License Agreement, the Joint Venture paid the Company ¥ ( approximately $47.8 million based on foreign exchange rates as of July 18, 2024) in exchange for the license to the Initial Records Batch (as defined in the Data License Agreement) and an additional ¥ (approximately $47.8 million based on foreign exchange rates as of July 18, 2024) pursuant to the IP License Agreement in exchange for a non-exclusive license with respect to certain of the Company’s technologies for certain specified uses solely in Japan. Under the Services Agreement, the Company will provide the Joint Venture with certain services. The foreign exchange gain/loss on the exchange of funds on July 18, 2024 upon closing of the Joint Venture was not material.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The condensed consolidated financial statements include the accounts of Tempus AI, Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial information and include the assets, liabilities, revenue and expenses of all wholly owned subsidiaries. Investments in unconsolidated entities in which the Company does not have a controlling financial interest, but has the ability to exercise significant influence, are accounted for under the equity method of accounting. Investments in unconsolidated entities in which the Company is not able to exercise significant influence are accounted for under the cost method of accounting. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been omitted. Accordingly, the unaudited interim condensed conde nsed In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of June 30, 2024 and its results of operations for the three and six months ended June 30, 2024 and 2023, and cash flows for the six months ended June 30, 2024 and 2023. The condensed consolidated balance sheet at December 31, 2023, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The Company believes that its existing cash and cash equivalents and marketable equity securities at June 30, 2024 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year from the date of issuance. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company’s cost structure. Future capital requirements will depend on many factors, including the timing and extent of spending on research and development activities and growth related expenditures. Other than described below, there have been no changes to the Company’s significant accounting policies described in the “Notes to the Consolidated Financial Statements” included in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Prospectus that have had a material impact on the Company’s consolidated financial statements and accompanying notes.
Reclassification	Reclassification Certain prior year amounts have been reclassified for consistency with the current year presentation.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging condensed
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities, revenue and expenses, and the related disclosures of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. The most significant estimates are related to revenue, accounts receivable, stock-based compensation, operating lease liabilities, and the useful lives of property, equipment and intangible assets. Actual results could differ from those estimates.
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders Basic and diluted net loss per share attributable to common stockholders is presented in conformity with two-class two-class
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs consist primarily of accounting, legal, and other fees related to the IPO. The Company had $ million of deferred offering costs as of December 31, 2023. Prior to the IPO, deferred offering costs were capitalized on the consolidated balance sheets. Upon the consummation of the IPO, $ million of deferred offering costs were reclassified into additional paid-in capital as an offset against IPO proceeds.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which provides enhanced disclosures about significant segment expenses. The standard also enhances interim disclosure requirements and provides new segment disclosure requirements for entities with a single reportable segment. The standard is effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods presented. Early adoption is permitted. The Company is currently evaluating the effect that this guidance will have on the consolidated financial statements and related disclosures. In 2023-09, 2023-09

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue Recognition [Abstract]
Summary of Warrant Contract Asset	The following summarizes the warrant contract asset presentation as of June 30, 2024 and December 31, 2023 (in thousands): June 30, 2024 December 31, 2023 Prepaid expenses and other current assets $ 4,843 $ 4,843 Warrant contract asset, less current portion 19,077 21,499 Total warrant contract asset $ 23,920 $ 26,342

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Summary of Property and Equipment	The following summarizes property and equipment, net as of June 30, 2024 and December 31, 2023 (in thousands): June 30, 2024 December 31, 2023 Equipment $ 101,631 $ 91,656 Leasehold improvements 44,000 42,433 Furniture and fixtures 6,633 6,633 Total property and equipment, gross 152,264 140,722 Less: accumulated depreciation (91,725 ) (79,041 ) Property and equipment, net $ 60,539 $ 61,681
Summary of Depreciation Expenses on Property and Equipment	Depreciation expense on property and equipment is classified as follows in the accompanying c ondensed Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Cost of revenue, genomics $ 3,293 $ 3,222 $ 6,674 $ 6,363 Selling, general and administrative costs 3,122 1,972 6,010 3,891 Total depreciation $ 6,415 $ 5,194 $ 12,684 $ 10,254
Summary of Accrued Expenses	Accrued expenses as of June 30, 2024 and December 31, 2023, consist of the following (in thousands): June 30, 2024 December 31, 2023 Accrued compensation and employee benefits $ 18,532   $ 21,950 Accrued expenses 44,053 37,783 Accrued cloud storage costs 13,723 13,921 Interest payable 8,877 8,863 Total accrued expenses $ 85,185 $ 82,517

Goodwill and Intangibles (Table

Goodwill and Intangibles (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	The following table summarizes intangible assets as of June 30, 2024 and December 31, 2023 (in thousands): June 30, 2024 December 31, 2023 Gross Amount Accumulated Net Gross Amount Accumulated Net Customer relationships $ 20,550 $ 13,913 $ 6,637 $ 20,550 $ 12,219 $ 8,331 Licensed data 19,321 14,868 4,453 19,321 11,469 7,852 Website domain 19 —  19 19 —  19 Trade names 8,000 2,857 5,143 8,000 2,286 5,714 $ 47,891 $ 31,638 $ 16,252 $ 47,890 $ 25,974 $ 21,916

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2024
Temporary Equity Disclosure [Abstract]
Summary of Redeemable Convertible Preferred Stock Outstanding	Redeemable convertible preferred stock outstanding as of December 31, 2023 consisted of the following (in thousands, except share amounts): As of December 31, 2023 Series Year Shares Liquidation Carrying Preferred Issued Authorized Outstanding Amount Value Series A 2015 10,000,000 10,000,000 $ 10,500 $ 10,000 Series B 2016 5,374,899 5,374,899 10,500 10,000 Series B-1 2016 2,500,000 2,500,000 10,500 10,000 Series B-2 2017 4,191,173 4,191,173 31,500 30,000 Series C 2017 9,779,403 9,779,403 86,757 70,000 Series D 2018 8,534,330 8,534,330 105,107 104,145 Series E 2018 6,630,905 6,630,905 151,621 151,621 Series F 2019 8,077,674 8,077,674 261,722 261,722 Series G 2020 2,537,290 2,537,290 119,928 119,928 Series G-2* 2020/2021 3,453,139 3,453,139 197,889 197,889 Series G-3** 2022/2023 4,362,476 1,661,895 98,891 95,238 Series G-4** 2023 4,362,476 785,245 45,514 45,000 Total convertible preferred stock 69,803,765 63,525,953 1,130,429 1,105,543 * Excludes amounts related to the conversion of convertible note ** Excludes amounts related to embedded conversion features

Stock-based compensation (Table

Stock-based compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense Recorded in Consolidated Statements of Operations	Stock-based compensation is classified as follows in the accompanying condensed Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Cost of revenues, genomics $ 11,327 $ —  $ 11,327 $ —  Cost of revenues, data and services 7,229 —  7,229 —  Technology research and development 50,434 —  50,434 —  Research and development 42,233 —  42,233 —  Selling, general and administrative 377,090 —  377,090 —  Total stock-based compensation $ 488,313 $ —  $ 488,313 $ —
Schedule of the activity related to the Company's RSUs	The table below summarizes restricted stock unit activity under the 2015 Plan for the six months ended June 30, 2024: Restricted Stock Units Weighted - Grant Date Fair Value Unvested at December 31, 2023 20,788,500 $ 26.47 Granted 1,933,606 $ 37.59 Vested and settled (4,563,164 ) $ 11.93 Vested and not yet settled (10,870,652 ) $ 24.46 Forfeited (457,785 ) $ 25.58 Expired (147,376 ) $ 0.28 Unvested at June 30, 2024 6,683,129 $ 36.77

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Calculation for Basic and Diluted Net Loss Per Share	The following table presents the calculation for basic and diluted net loss per share (in thousands, except share and per share data): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator: Net loss $ (552,212 ) $ (55,832 ) $ (616,955 ) $ (110,209 ) Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares (11,540 ) (10,897 ) (39,347 ) (21,566 ) Cumulative Undeclared Dividends on Series C preferred shares (668 ) (745 ) (1,174 ) (1,466 ) Net loss attributable to common stockholders $ (564,420 ) $ (67,474 ) $ (657,476 ) $ (133,241 ) Denominator: Weighted-average common shares outstanding, basic and diluted 82,325 63,286 72,930 63,257 Net loss per share attributable to common stockholders, basic and diluted $ (6.86 ) $ (1.07 ) $ (9.02 ) $ (2.11 )
Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share	The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share for each period, as the impact of including them would have been anti-dilutive. As disclosed in Note 8, the Company issued a warrant for $100 million in shares of the Company’s Class A common stock. As per the terms of th e As of June 30, 2024 2023 Stock options outstanding 210,000 210,000 AstraZeneca warrant 2,702,703 1,744,991 Mpirik holdback liability —  8,724 SEngine holdback liability 41,007 —  Sengine contingent consideration 35,000 —  Unvested RSUs 6,683,129 —  Total potentially dilutive shares 9,671,839 1,963,715

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Portion of Unrealized Gains Relate to Marketable Equity Securities	The following summarizes the portion of unrealized gains recorded during the three and six months ended June 30, 2024 that relate to marketable securities held as of June 30, 2024 (in thousands): Three Months Ended Six Months Ended June 30, 2024 June 30, 2024 Net (loss) gain during the period on marketable equity securities $ (3,705 ) $ 2,541 Less: Net gain recognized during the period on marketable equity securities sold during the period —  (6,081 ) Unrealized gain recognized during the period on marketable equity securities still held at the reporting date $ (3,705 ) $ (3,540 )
Schedule of the Assumption Used in the Model Table	The following table summarizes the assumptions used in the model as of June 30, 2024: Expected term (in years) 2.50 Risk-free interest rate 4.51 % Expected volatility 55.00 % Expected dividend yield 0.00 %
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables summarize assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Fair Value Measurement at Reporting Date Using June 30, 2024 Quoted Price in (Level 1) Significant Other (Level 2) Significant Assets Marketable equity securities $ 11,255 $ 11,255 $ —  $ —  Warrant asset $ 2,300 $ —  $ 2,300 $ —  Liabilities Warrant liability $ 33,600 $ —  $ —  $ 33,600 Contingent consideration $ 940 $ 940 $ —  $ —  Fair Value Measurement at Reporting Date Using December 31, 2023 Quoted Price in Significant Other Significant Assets Marketable equity securities $ 31,807 $ 31,807 $ —  $ —  Warrant asset $ 10,000 $ —  $ 10,000 $ —  Liabilities Warrant liability $ 34,500 $ —  $ —  $ 34,500 Contingent consideration $ 775 $ —  $ —  $ 775
Schedule of Fair Value Assets and Liabilty Measured on Unobservable Input Reconciliation	The following tables provide a reconciliation of the beginning and ending balances for the assets and liabilities measured at fair value using significant unobservable inputs (Level 3) (in thousands): Warrant Liability Contingent Balance at December 31, 2023 $ 34,500 $ 775 Change in fair value of warrant liability (900 ) —  Change in fair value of contingent consideration —  194 Transfer out of Level 3 —  (969 ) Balance at June 30, 2024 $ 33,600 $ —  Warrant Liability Contingent Balance at December 31, 2022 $ 42,500 $ —  Contingent consideration from Mpirik acquisition —  400 Change in fair value of warrant liability (5,700 ) —  Balance at June $ 36,800 $ 400

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended		6 Months Ended
	Jun. 17, 2024	Jun. 16, 2024	Dec. 08, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Apr. 30, 2022	Dec. 31, 2021
Nature Of Operations [Line Items]
Allocated share based compensation				$ 488,313	$ 0	$ 488,313	$ 0
Temporary equity shares authorized								69,803,765
Common stock shares converted from one class to another	331,110
IPO [Member]
Nature Of Operations [Line Items]
Temporary equity shares authorized	20,000,000
Restricted Stock Units (RSUs) [Member] | IPO [Member]
Nature Of Operations [Line Items]
Shares issued, price per share	$ 37
Allocated share based compensation						$ 488,300
Adjustment related to tax witholding for share based compensation	$ 70,800
Restricted stock units vested during the period	4,568,291
Common Class A [Member]
Nature Of Operations [Line Items]
Common stock shares authorized				1,000,000,000		1,000,000,000		200,228,024	204,590,500	200,228,024
Common stock shares outstanding				149,274,923		149,274,923		58,367,961
Common Class A [Member] | IPO [Member]
Nature Of Operations [Line Items]
Stock issued during period, shares, new issues	11,100,000
Shares issued, price per share	$ 37
Proceeds from initial public offering	$ 382,000
Stock issuance costs	$ 28,700
Common stock shares authorized	1,000,000,000
Common Class A [Member] | Restricted Stock Units (RSUs) [Member]
Nature Of Operations [Line Items]
Share-based payment arrangement, shares withheld for tax withholding obligation	1,911,316
Restricted stock shares issued during the period net of forfeitures shares	4,563,164
Common Class B [Member]
Nature Of Operations [Line Items]
Common stock shares authorized				5,500,000		5,500,000		5,374,899		5,374,899
Common stock shares outstanding	5,043,789			5,043,789		5,043,789		0
Common Class B [Member] | IPO [Member]
Nature Of Operations [Line Items]
Common stock shares authorized	5,500,000
Series A To Series G Redeemable Convertible Preferred Stock Other Than Class B [Member]
Nature Of Operations [Line Items]
Temporary equity converted into permanent equity common stock shares	66,309,550
Series B B One And B Two Redeemable Convertible Preferred Stock [Member]
Nature Of Operations [Line Items]
Temporary equity converted into permanent equity common stock shares	5,374,899
Series G Three Redeemable Convertible Preferred Stock [Member] | Investor Agreement With Series G Three Redeemable Preferred Stockholders [Member]
Nature Of Operations [Line Items]
Stock issued during the period shares new issues to the holders of temporary equity	236,719
Class A Voting Common Stock [Member]
Nature Of Operations [Line Items]
Stock issued during the period value stock dividend		$ 188,200
Common stock dividend shares		5,098,799
Class A Voting Stock [Member]
Nature Of Operations [Line Items]
Conversion of non voting common stock into voting stock shares		5,069,477
Class A Voting Stock [Member] | Excercise Of Warrants [Member]
Nature Of Operations [Line Items]
Stock issued during period, shares, new issues			109,459

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Line Items]
Deferred offering costs	$ 0	$ 7,085
IPO [Member]
Accounting Policies [Line Items]
Adjustment to additional paid in capital stock issuance costs	$ 12,300
Deferred offering costs		$ 7,100

Revenue Recognition - Summary o

Revenue Recognition - Summary of Warrant Contract Asset (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Disclosure In Tabular Form Of Warrant Contract Asset As Per Balance Sheet Classification [Line Items]
Total warrant contract asset	$ 23,920	$ 26,342
Prepaid Expenses and Other Current Assets [Member]
Disclosure In Tabular Form Of Warrant Contract Asset As Per Balance Sheet Classification [Line Items]
Prepaid expenses and other current assets	4,843	4,843
Warrant Contract Asset Less Current Portion [Member]
Disclosure In Tabular Form Of Warrant Contract Asset As Per Balance Sheet Classification [Line Items]
Warrant contract asset, less current portion	$ 19,077	$ 21,499

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Nov. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax		$ 165,969	$ 132,417	$ 311,789	$ 248,041
Contract with customer liability amount of revenue recognized that was included in the opening balance				39,500	26,400
Accounts Receivable [Member]
Disaggregation of Revenue [Line Items]
Contract with customer receivable after allowance for credit loss current		9,300		9,300		$ 2,400
Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation		197,300		197,300
Commercialization and Reference Laboratory Agreement Member With Personalis Inc [Member]
Disaggregation of Revenue [Line Items]
Term of agreement	3 years
Personalis Inc [Member] | Commercialization and Reference Laboratory Agreement Member With Personalis Inc [Member]
Disaggregation of Revenue [Line Items]
Aggregate milestone amount payable	$ 12,000
Cumulative amount paid		7,000		7,000
Contract with customer assets net current		$ 1,100		$ 1,100		$ 100
Personalis Inc [Member] | Commercialization and Reference Laboratory Agreement [Member]
Disaggregation of Revenue [Line Items]
Class Of Warrant Share Issued		9,218,800		9,218,800
Personalis Inc [Member] | Commercialization and Reference Laboratory Agreement [Member] | Prior December 31 2024 [Member]
Disaggregation of Revenue [Line Items]
Class Of Warrant Excisable At Cash		4,609,400		4,609,400
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.5		$ 1.5
Personalis Inc [Member] | Commercialization and Reference Laboratory Agreement [Member] | Prior December 31 2025 [Member]
Disaggregation of Revenue [Line Items]
Class Of Warrant Excisable At Cash		4,609,400		4,609,400
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.5		$ 2.5
One Year [Member] | Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage		42%		42%
Two Year [Member] | Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage		34%		34%
Three Year [Member] | Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage		19%		19%
Four Year [Member] | Long-Term Contract with Customer [Member]
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage		5%		5%
Genomics Product [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax		$ 112,300	91,900	$ 214,900	174,000
Genomics Product [Member] | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax		10,600	7,500	19,800	17,100
Clinical Order [Member] | Third-Party Payor [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax		101,700	84,400	195,100	156,900
Insights Product [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax		40,700	29,100	72,000	51,900
Trials Product [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax		10,500	10,600	21,800	20,900
Data And Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customers excluding assessed tax		$ 53,600	$ 40,500	$ 96,900	$ 74,100

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands				1 Months Ended	6 Months Ended
	Oct. 03, 2023	Mar. 08, 2023	Oct. 03, 2022	Feb. 29, 2024	Jun. 30, 2024	Jun. 30, 2023	Jan. 01, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill					$ 73,345			$ 73,354
Payment to acquire business net of cash acquired					$ 0	$ 2,869
Sengine [Member]
Business Acquisition [Line Items]
Goodwill	$ 9,600
Business combination aggregate consideration transferred	9,900
Payments to acquire businesses, gross	2,800
Business combination consideration in the form of shares held back	1,400
Sengine [Member] | Maximum [Member]
Business Acquisition [Line Items]
Net working capital adjustment	100
Sengine [Member] | Nonvoting Common Stock [Member]
Business Acquisition [Line Items]
Business combination consideration transferred equity interests issued and issuable	$ 6,300
Business acquisition equity interests issued or issuable number of shares issued	35,000
Stock issued during the period shares towards working capital adjustment				429
Mpirik [Member]
Business Acquisition [Line Items]
Goodwill		$ 10,600
Business combination aggregate consideration transferred		9,700
Business combination consideration transferred equity interests issued and issuable		4,600
Business combination consideration in the form of shares held back		300
Net working capital adjustment		300
Business combination aggregate cash consideration payable including the amount witheld		4,700
Business combination contingent consideration payable in cash at fair value		400
Business combination cash consideration held back		800
Business combination contingent consideration liability based on revenue milestone		1,000
Estimated minimum revenue to be attained by the acquiree		$ 1,500
Business combination contingent consideration acquisition date fair value							$ 0
Mpirik [Member] | Restricted Stock Units (RSUs) [Member]
Business Acquisition [Line Items]
Stock issued during the period restricted stock award netof forfeitures		17,450
Mpirik [Member] | Other Current Liabilities [Member]
Business Acquisition [Line Items]
Business combination contingent consideration acquisition date fair value		$ 400
Mpirik [Member] | Nonvoting Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during the period shares in respect of consideration held back		8,724
Arterys [Member]
Business Acquisition [Line Items]
Goodwill			$ 11,100
Business combination consideration transferred equity interests issued and issuable			4,900
Cash consideration			3,000
Business combination fair value of consideration net of cash acquired			8,300
Cash acquired in a business combination			300
Payment to acquire business net of cash acquired			3,000
Payment of net working capital adjustment			$ 1,000

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Equipment	$ 101,631	$ 91,656
Leasehold improvements	44,000	42,433
Furniture and fixtures	6,633	6,633
Total property and equipment, gross	152,264	140,722
Less: accumulated depreciation	(91,725)	(79,041)
Property and equipment, net	$ 60,539	$ 61,681

Balance Sheet Components - Su_2

Balance Sheet Components - Summary of Depreciation Expenses on Property and Equipment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Property Plant and Equipment Income Statement Disclosures [Abstract]
Cost of revenue, genomics	$ 3,293	$ 3,222	$ 6,674	$ 6,363
Selling, general and administrative costs	3,122	1,972	6,010	3,891
Total depreciation	$ 6,415	$ 5,194	$ 12,684	$ 10,254

Balance Sheet Components - Su_3

Balance Sheet Components - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Accrued compensation and employee benefits	$ 18,532	$ 21,950
Accrued expenses	44,053	37,783
Accrued cloud storage costs	13,723	13,921
Interest payable	8,877	8,863
Total accrued expenses	$ 85,185	$ 82,517

Goodwill and Intangibles - Summ

Goodwill and Intangibles - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Finite And Indefinitely Lived Intangible Assets [Line Items]
Gross Amount	$ 47,891	$ 47,890
Accumulated Amortization	31,638	25,974
Net	16,252	21,916
Website domain [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Indefinite lived intangible sssets	19	19
Customer relationships [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Gross Amount	20,550	20,550
Accumulated Amortization	13,913	12,219
Net	6,637	8,331
Licensed data [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Gross Amount	19,321	19,321
Accumulated Amortization	14,868	11,469
Net	4,453	7,852
Trade names [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Gross Amount	8,000	8,000
Accumulated Amortization	2,857	2,286
Net	$ 5,143	$ 5,714

Goodwill and Intangibles - Addi

Goodwill and Intangibles - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Finite And Indefinitely Lived Intangible Assets [Line Items]
Goodwill, acquired during period	$ 0	$ 0	$ 0
Goodwill, impairment loss	0	0	0	$ 0
Impairment of intangible assets, finite-lived	0	0	0	0
Operating Cost and Expenses [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 2,800,000	3,100,000	$ 5,700,000	6,000,000
Mpirik [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Goodwill, acquired during period				10,600,000
Maximum [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	7 years		7 years
Minimum [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	3 years		3 years
Weighted Average [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	6 years		6 years
Licensed Data [Member] | DeIdendified Data Through Additional Agreement [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Additions to finite lived intangible assets		$ 0		3,800,000
Licensed Data [Member] | Research And Development Process [Member]
Finite And Indefinitely Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived				7,400,000
Gain loss due to saving in future payments due on intangible assets				$ 7,900,000
Reduction in gross value of intangible assets			$ 40,100,000
Reduction in accumulated amortization of finite lived intangible assets			$ 32,700,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Millions		1 Months Ended	6 Months Ended
	Dec. 08, 2023 $ / shares shares	Jan. 31, 2023 shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 shares	Dec. 31, 2023 shares	Apr. 30, 2022 shares	Dec. 31, 2021 USD ($) $ / shares shares
Class of Stock [Line Items]
Preferred stock shares authorized			20,000,000
Treasury Stock, Common [Member]
Class of Stock [Line Items]
Stock repurchased during the period shares				(145,466)
Allen and Company LLC [Member] | Warrants Convertible Into Class A Common Stock [Member]
Class of Stock [Line Items]
Class of warrants or rights number of securities covered by warrants or rights	150,000
Class of warrants or rights exercise price | $ / shares	$ 10
Common Class A [Member]
Class of Stock [Line Items]
Common stock shares authorized			1,000,000,000		200,228,024	204,590,500	200,228,024
Common Class A [Member] | Exercise of Warrants [Member]
Class of Stock [Line Items]
Stock issued during period shares new issues	109,459
Common Class A [Member] | Master Services Agreement With Astra Zeneca As Amended [Member]
Class of Stock [Line Items]
Class of warrants value of shares covered by warrants or rights | $							$ 100
Class of warrants or rights number of securities covered by warrants or rights							2,702,703
Class of warrants or rights exercise price | $ / shares							$ 37
Commitment of the counterparty | $			$ 220
Commitment of the counterparty if warrants are exercised | $			$ 320
Common Class B [Member]
Class of Stock [Line Items]
Common stock shares authorized			5,500,000		5,374,899		5,374,899
Stockholders equity stock split			1
Duration before which shares may be converted from one class to another			20 years
Share holding below which trigger is caused for conversion of stock from one class to another			10,000,000
Common Class B [Member] | Maximum [Member]
Class of Stock [Line Items]
Number of days for determining conversion of stock from class to another			150 days
Number of days for determining ownership of the founder below which conversion of stock from one class to another is triggered			150 days
Common Class B [Member] | Minimum [Member]
Class of Stock [Line Items]
Number of days for determining conversion of stock from class to another			90 days
Number of days for determining ownership of the founder below which conversion of stock from one class to another is triggered			90 days
Non-voting Common Stock [Member]
Class of Stock [Line Items]
Common stock shares authorized			0		66,946,627		63,946,627
Non-voting Common Stock [Member] | Treasury Stock, Common [Member]
Class of Stock [Line Items]
Stock repurchased during the period shares		145,466

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock Outstanding (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Temporary Equity [Line Items]
Shares Authorized		69,803,765
Shares Outstanding		63,525,953
Liquidation Amount		$ 1,130,429
Carrying Value	$ 0	$ 1,105,543
Series A [Member]
Temporary Equity [Line Items]
Shares Authorized		10,000,000
Shares Outstanding		10,000,000
Liquidation Amount		$ 10,500
Carrying Value		$ 10,000
Series B [Member]
Temporary Equity [Line Items]
Shares Authorized		5,374,899
Shares Outstanding		5,374,899
Liquidation Amount		$ 10,500
Carrying Value		$ 10,000
Series B-1 [Member]
Temporary Equity [Line Items]
Shares Authorized		2,500,000
Shares Outstanding		2,500,000
Liquidation Amount		$ 10,500
Carrying Value		$ 10,000
Series B-2 [Member]
Temporary Equity [Line Items]
Shares Authorized		4,191,173
Shares Outstanding		4,191,173
Liquidation Amount		$ 31,500
Carrying Value		$ 30,000
Series C [Member]
Temporary Equity [Line Items]
Shares Authorized		9,779,403
Shares Outstanding		9,779,403
Liquidation Amount		$ 86,757
Carrying Value		$ 70,000
Series D [Member]
Temporary Equity [Line Items]
Shares Authorized		8,534,330
Shares Outstanding		8,534,330
Liquidation Amount		$ 105,107
Carrying Value		$ 104,145
Series E [Member]
Temporary Equity [Line Items]
Shares Authorized		6,630,905
Shares Outstanding		6,630,905
Liquidation Amount		$ 151,621
Carrying Value		$ 151,621
Series F [Member]
Temporary Equity [Line Items]
Shares Authorized		8,077,674
Shares Outstanding		8,077,674
Liquidation Amount		$ 261,722
Carrying Value		$ 261,722
Series G [Member]
Temporary Equity [Line Items]
Shares Authorized		2,537,290
Shares Outstanding		2,537,290
Liquidation Amount		$ 119,928
Carrying Value		$ 119,928
Series G-2 [Member]
Temporary Equity [Line Items]
Shares Authorized		3,453,139
Shares Outstanding		3,453,139
Liquidation Amount		$ 197,889
Carrying Value		$ 197,889
Series G-3 [Member]
Temporary Equity [Line Items]
Shares Authorized		4,362,476
Shares Outstanding		1,661,895
Liquidation Amount		$ 98,891
Carrying Value		$ 95,238
Series G-4 [Member]
Temporary Equity [Line Items]
Shares Authorized		4,362,476
Shares Outstanding		785,245
Liquidation Amount		$ 45,514
Carrying Value		$ 45,000

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended	6 Months Ended
	Apr. 30, 2024	Jan. 31, 2024	Oct. 31, 2023	Jan. 31, 2023	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 17, 2024	Dec. 31, 2023
Temporary Equity [Line Items]
Proceeds from redeemable convertible preferred stock						$ 199,750	$ 0
Series G-3 Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity stock issued during the period shares payment of dividend in kind		66,465		47,781
Series G-4 Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity stock issued during the period shares payment of dividend in kind		10,666
Series G-5 Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity stock issued during the period shares new issues	3,489,981		785,245
Proceeds from redeemable convertible preferred stock	$ 200,000		$ 45,000
Temporary equity par or stated value per share	$ 0.0001		$ 0.0001
Temporary equity special payment as a percentage of original issue price			5%
Aggregate trading period for determining special price payable to the holders of temporary equity			10 days
Common stock average price as percentage of issue price maximum			110%
Series G-5 Redeemable Convertible Preferred Stock [Member] | Accrued Liabilities [Member]
Temporary Equity [Line Items]
Special price payable current					$ 2,300	$ 2,300
Common Class A [Member]
Temporary Equity [Line Items]
Common stock shares outstanding					149,274,923	149,274,923			58,367,961
Temporary equity converted into permanent equity shares					71,976,178
Common Class B [Member]
Temporary Equity [Line Items]
Common stock shares outstanding					5,043,789	5,043,789		5,043,789	0

Stock-based compensation - Addi

Stock-based compensation - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
2015 Stock Option Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award number of shares authorized for issue						28,115,750
2015 Stock Option Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award equity instruments other than options granted during the period		1,647,906		1,933,606
Share based compensation by share based award incremental compensation costs		$ 47.5	$ 35.3	$ 47.5	$ 35.3
Share based compensation by share based award vesting period		4 years
Share based compensation by share based award unrecognized compensation equity instruments other than options		$ 125.3		$ 125.3
Share based compensation by share based award unrecognized compensation remaining period for recognition		1 year 4 months 24 days
2015 Stock Option Plan [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award vesting percentage		20%
2024 Equity Incentive Plan [Member] | Incentive Stock Options [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award number of shares available for issue		22,290,000		22,290,000
2024 Equity Incentive Plan [Member] | Common Class A [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award number of shares available for issue		7,430,000		7,430,000
Share based compensation by share based payment award expiration date	Jan. 01, 2034
2024 Equity Incentive Plan [Member] | Class A And Class B Common Stock [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award number of additional shares available for issue as a percentage of outstanding common stock		5%		5%

Stock-based compensation - Sche

Stock-based compensation - Schedule of the activity related to the Company's RSUs (Detail) - Two Thousand and Fifteen Plan [Member] - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unvested at December 31, 2023 | shares	20,788,500
Granted | shares	1,933,606
Vested and settled | shares	(4,563,164)
Vested and not yet settled | shares	(10,870,652)
Forfeited | shares	(457,785)
Expired | shares	(147,376)
Unvested at June 30, 2024 | shares	6,683,129
Unvested at December 31, 2023 | $ / shares	$ 26.47
Granted | $ / shares	37.59
Vested and settled | $ / shares	11.93
Vested and not yet settled | $ / shares	24.46
Forfeited | $ / shares	25.58
Expired | $ / shares	0.28
Unvested at June 30, 2024 | $ / shares	$ 36.77

Stock-based compensation - Sc_2

Stock-based compensation - Schedule of Stock-based Compensation Expense Recorded in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense	$ 488,313	$ 0	$ 488,313	$ 0
Cost of Revenue Genomics [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense	11,327	0	11,327	0
Cost of Revenue Data and Services [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense	7,229	0	7,229	0
Technology Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense	50,434	0	50,434	0
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense	42,233	0	42,233	0
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, expense	$ 377,090	$ 0	$ 377,090	$ 0

Debt - Additional Information (

Debt - Additional Information (Detail)

3 Months Ended

6 Months Ended

12 Months Ended

Oct. 11, 2023 USD ($)

Nov. 19, 2020 USD ($)

Jun. 22, 2020 USD ($) Day

Jun. 30, 2024 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2024 USD ($)

Jun. 30, 2023 USD ($)

Dec. 31, 2025 USD ($)

Dec. 31, 2024 USD ($)

Dec. 31, 2023 USD ($)

Apr. 25, 2023 USD ($)

Sep. 22, 2022 USD ($)

Debt Instrument [Line Items]

Proceeds from long term debt net of issuance costs and discount

$ 0

$ 48,750,000

Payment of interest on debt

13,921,000

5,691,000

Fed Funds Effective Rate Overnight Index Swap Rate [Member]

Debt Instrument [Line Items]

Debt instrument variable interest rate spread percentage based on which the borrowing type can be converted into base rate

0.50%

Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]

Debt Instrument [Line Items]

Debt instrument variable interest rate spread percentage based on which the borrowing type can be converted into base rate

1%

Term Loan Agreement With Ares Capital Corporation [Member]

Debt Instrument [Line Items]

Debt instrument face value

$ 175,000,000

$ 175,000,000

$ 175,000,000

Long term debt unamortized discount gross

4,400,000

Long term debt unamortized debt issuance costs gross

$ 2,600,000

Long term debt variable interest rate percentage

9.89%

9.89%

Term Loan Amendment Agreement One With Ares Capital Corporation [Member]

Debt Instrument [Line Items]

Debt instrument face value

$ 50,000,000

$ 50,000,000

$ 50,000,000

Long term debt unamortized discount gross

$ 1,300,000

Increase in interest rate percentage on term loan facility

0.25%

Long term debt variable interest rate percentage

10.07%

10.07%

Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital Corporation [Member]

Debt Instrument [Line Items]

Long term debt unamortized discount gross

$ 6,500,000

$ 4,500,000

4,500,000

$ 5,100,000

Long term debt unamortized debt issuance costs gross

2,600,000

Minimum liquidity required to be maintained value

$ 25,000,000

Long term debt unamortized debt issuance costs net

$ 1,600,000

1,600,000

$ 1,900,000

Payment of interest on debt

$ 13,900,000

Long term debt variable interest rate percentage

10.30%

10.30%

Interest expenses

$ 9,200,000

$ 6,900,000

$ 18,300,000

$ 12,000,000

Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital Corporation [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]

Debt Instrument [Line Items]

Debt instrument variable interest rate spread percentage

5%

Debt instument paid in kind interest percentage

3.25%

Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital Corporation [Member] | Base Rate [Member]

Debt Instrument [Line Items]

Debt instrument variable interest rate spread percentage

4%

Debt instument paid in kind interest percentage

3.25%

Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital Corporation [Member] | Base Rate One [Member]

Debt Instrument [Line Items]

Debt instrument variable interest rate spread percentage

6.25%

Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital Corporation [Member] | Term Secured Overnight Financing Rate One [Member]

Debt Instrument [Line Items]

Debt instrument variable interest rate spread percentage

7.25%

Term Loan Amendment Agreement Two With Ares Capital Corporation [Member]

Debt Instrument [Line Items]

Debt instrument face value

$ 35,000,000

Long term debt unamortized discount gross

900,000

Proceeds from long term debt net of issuance costs and discount

$ 34,100,000

Long term debt maturity date

Sep. 22, 2027

Term Loan Amendment Agreement Two With Ares Capital Corporation [Member] | SOFR One [Member]

Debt Instrument [Line Items]

Debt instrument variable interest rate spread percentage based on which the borrowing type can be converted into base rate

2%

Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Debt instrument face value

$ 330,000,000

Fair value of liabilities measured using significant unobservable input issues during the period

330,000,000

Amended And Restated Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Debt instrument face value

$ 250,000,000

Long term debt maturity date

Mar. 22, 2026

Interest expenses

$ 3,700,000

$ 3,800,000

$ 7,300,000

$ 7,600,000

Principal amount to be payable after prepayment value

$ 150,000,000

Debt instrument convertible threshold period of consecutive trading days | Day

20

Forecast [Member] | Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital Corporation [Member] | Twelve Months Ended Thirty First Of December Two Thousand And Twenty Four [Member]

Debt Instrument [Line Items]

Revenue

$ 459,100,000

Forecast [Member] | Term Loan Agreement Including Amendment Agreement One And Two With Ares Capital Corporation [Member] | Twelve Months Ended Thirty First Of December Two Thousand And Twenty Five [Member]

Debt Instrument [Line Items]

Revenue

$ 594,100,000

Series G Two Redeemable Convertible Preferred Stock [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Temporary equity stock issued during period value new issues

$ 80,000,000

Redeemable preferred stock discount rate percentage

10%

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Calculation for Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator:
Net Income (Loss)	$ (552,212)	$ (55,832)	$ (616,955)	$ (110,209)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares	(11,540)	(10,897)	(39,347)	(21,566)
Cumulative Undeclared Dividends on Series C preferred shares	(668)	(745)	(1,174)	(1,466)
Net loss attributable to common stockholders, Basic	(564,420)	(67,474)	(657,476)	(133,241)
Net loss attributable to common stockholders, Diluted	$ (564,420)	$ (67,474)	$ (657,476)	$ (133,241)
Denominator:
Weighted-average common shares outstanding, basic	82,325	63,286	72,930	63,257
Weighted-average common shares outstanding, diluted	82,325	63,286	72,930	63,257
Net loss per share attributable to common stockholders, basic	$ (6.86)	$ (1.07)	$ (9.02)	$ (2.11)
Net loss per share attributable to common stockholders, diluted	$ (6.86)	$ (1.07)	$ (9.02)	$ (2.11)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	9,671,839	1,963,715
Stock options outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	210,000	210,000
AstraZeneca warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	2,702,703	1,744,991
Mpirik holdback liability [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		8,724
SEngine holdback liability [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	41,007
Sengine contingent consideration [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	35,000
Unvested RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	6,683,129

Net Loss Per Share Attributab_5

Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) $ in Millions	1 Months Ended
	Oct. 31, 2022 USD ($)
Class A Voting Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Class of warrants or rights issued during the period value	$ 100

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Maximum [Member]
Income Tax [Line Items]
Income tax expense (benefit)	$ 0.2	$ 0.2	$ 0.2	$ 0.2

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ / shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure	$ 940		$ 940		$ 775
Proceeds from sale of marketable equity securities			$ 23,098	$ 0
Investment In Recursion Pharmaceuticals Class A Common Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in equity securities at fair value sold number of shares			1,725,902
Weighted average price per share of investment sold			$ 13,380
Proceeds from sale of marketable equity securities			$ 23,100
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure	940		940		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration classified as equity, fair value disclosure	0		0		775
Company recognised expenses due change fair value of warrant liability	1,700	$ 700
Company recognized gain due change fair value of warrant liability			900	$ 5,700
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant issued			100,000
Contingent Consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration cash payment			1,000
Contingent upon revenue target					$ 1,500
Contingent consideration classified as equity, fair value disclosure	$ 800		$ 800
Contingent Consideration [Member] | Common Stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration arrangement of non voting common stock			35,000
Contingent Consideration [Member] | Common Stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration arrangement of non voting common stock			35,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Portion of Unrealized Gains Relate to Marketable Equity Securities (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Gain (Loss) on Securities [Line Items]
Net (loss) gain during the period on marketable equity securities	$ (3,705)	$ 2,541	$ 0
Less: Net gain recognized during the period on marketable equity securities sold during the period	0	(6,081)
Unrealized gain recognized during the period on marketable equity securities still held at the reporting date	$ (3,705)	$ (3,540)

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of the Assumption Used in the Model Table (Detail)	Jun. 30, 2024 yr
Expected term (in years) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	2.5
Risk-free interest rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	4.51
Expected volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	55
Expected dividend yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Assets, Fair Value Disclosure [Abstract]
Marketable equity securities	$ 11,255	$ 31,807
Warrant asset	2,300	10,000
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	33,600	34,500
Contingent consideration	940	775
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Marketable equity securities	11,255	31,807
Warrant asset	0	0
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	0	0
Contingent consideration	940	0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Marketable equity securities	0	0
Warrant asset	2,300	10,000
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	0	0
Contingent consideration	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Marketable equity securities	0	0
Warrant asset	0	0
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	33,600	34,500
Contingent consideration	$ 0	$ 775

Fair Value Measurements - Sch_4

Fair Value Measurements - Schedule of Fair Value Assets and Liabilty Measured on Unobservable Input Reconciliation (Detail) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Warrant Liability [Member]
Fair Value Assets And Liability Measured On Unobservable Input Reconciliation [Line Items]
Beginning balances for the assets and liabilities measured at fair value	$ 34,500	$ 42,500
Change in fair value of warrant liability	(900)	(5,700)
Contingent consideration from Mpirik acquisition		0
Change in fair value of contingent consideration	0
Transfer out of Level 3	0
Ending balances for the assets and liabilities measured at fair value	33,600	36,800
Contingent Consideration [Member]
Fair Value Assets And Liability Measured On Unobservable Input Reconciliation [Line Items]
Beginning balances for the assets and liabilities measured at fair value	775	0
Change in fair value of warrant liability	0	0
Contingent consideration from Mpirik acquisition		400
Change in fair value of contingent consideration	194
Transfer out of Level 3	(969)
Ending balances for the assets and liabilities measured at fair value	$ 0	$ 400

Related Parties - Additional In

Related Parties - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Aug. 19, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2018	Dec. 31, 2023
Related Party [Member]
Related Party Transaction [Line Items]
Aamount receive from related party						$ 1,500
Related party transaction due from to related party		$ 700		$ 700			$ 700
Pathos [Member]
Related Party Transaction [Line Items]
Due to related parties		0		0			0
Pathos [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Related party transaction due from to related party		100		100			$ 100
Revenue from the arrangement		300	$ 300	300	$ 300
Revenue from the additional arrangement		100	100	100	100
Pathos [Member] | Subscription Arrangement [Member]
Related Party Transaction [Line Items]
Subscription fee payable for year wise	$ 400
Revenue from subscription fee		$ 100	$ 200	$ 100	$ 200
Warrant [Member] | Pathos [Member]
Related Party Transaction [Line Items]
Received warrant to purchase share	23,456,790
Percentage of current outstanding equity	19%
Common stock par or stated value per share	$ 0.0125
Warrant optional exercise election window term	10 days of the 20 year term

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Jul. 18, 2024 - Subsequent Event [Member] $ in Millions	USD ($)	JPY (¥)	JPY (¥)
Investment In Japan Joint Venture Pursuant to Joint Venture Agreement [Member]
Subsequent Event [Line Items]
Equity method investment ownership percentage	50%		50%
Co-venturer [Member] | Investment In Japan Joint Venture Pursuant to Joint Venture Agreement [Member]
Subsequent Event [Line Items]
Equity method investment ownership percentage	50%		50%
Corporate Joint Venture Between the Company and the Soft Bank Group Japan [Member]
Subsequent Event [Line Items]
Common stock value	$ 191.1		¥ 30,000,000,000
Corporate Joint Venture Between the Company and the Soft Bank Group Japan [Member] | Data License Agreement [Member]
Subsequent Event [Line Items]
Proceeds from license fees	47.8	¥ 7,500,000,000
Corporate Joint Venture Between the Company and the Soft Bank Group Japan [Member] | Intellectual Property License Agreement [Member]
Subsequent Event [Line Items]
Proceeds from license fees	$ 47.8	¥ 7,500,000,000